Shares in the ASX 200 biotechnology company closed out 2022 trading for $287.76. When the closing bell rang on 31 March, those same shares were trading for $288.30, up 0.2%.

While that put the CSL share price in positive territory for Q1 2023, it underperformed the benchmark index, which gained 2% over the three months.

Here's how the quarter unfolded.

What happened over the first quarter?

If you have a look at the price chart at the end of this article, you'll see that the CSL share price enjoyed a strong run in the early weeks of 2023.

On 3 February, shares closed at $313.81, notching fresh one-year highs.

Alongside the broader rising market at the time, the biotech giant looks to have benefited from some positive broker coverage.

Morgans was among those bullish brokers, adding CSL to its best ideas list for February. Morgans has a price target for CSL shares of $312.20.

Morgan Stanley also was positive on the company's stock, reaffirming its overweight rating with a $354 price target.

From 3 February through to 31 March, the CSL share price went the other direction though, falling 8.1% over that period.

One headwind could be that investors were pricing in news released on 3 February that GSK plc (NYSE: GSK), a rival biotech stock, had received approval from the United States Food and Drug Administration for a competing drug to treat anaemia caused by chronic kidney disease.

CSL also reported its half-year results on 14 February.

The biotech company reported a 19% year-on-year increase in total revenue for the six months to US$7.2 billion.

But profits were hit by currency headwinds and increased acquisition costs. This saw net profit after tax (NPAT) decline 8% year on year to US$1.6 billion.

The CSL share price also slipped 2.2% on 9 March. That's the day it traded without rights to the interim dividend of $1.62, unfranked.

CSL share price snapshot

As you can see in the chart below, the CSL has enjoyed a strong start to April, with shares up 5% so far this month.

The post <strong>Why did the CSL share price lag the ASX 200 in the first quarter of 2023?</strong> appeared first on The Motley Fool Australia.

The software-as-a-service (Saas) company also advised today that two new executives will be joining its board as strategic advisors.

Let's look further into the company's announcements.

Wheezo UK launch

The Respiri share price was temporarily boosted today after the company stated it plans to launch Wheezo in the UK. The combination app and device product aims to help those with asthma manage the condition. The company said it is on track to launch in the UK market in late 2021.

This comes after Respiri's news on Tuesday that Wheezo has received United States Food and Drug Administration (FDA) clearance.

Respiri is in discussions with multinational pharmaceutical company Cipla and other potential partners ahead of Wheezo's UK launch.

Further, Respiri states it's in discussions with leading clinicians in the UK regarding the company's participation as a technology partner in multiple, large, asthma-related studies. These studies are expected to provide evidence for the use of asthma therapeutics and the role of digital technologies in the management of paediatric asthma.

The company says better asthma management has the potential to lead to improved outcomes and quality of life for those with the condition.

Advisor appointments to Respiri board

In further news impacting the Respiri share price this morning, the company also announced it has recently appointed two new advisors to its board.

Dr Andrew Weekes and Dr Mark Levy will aid the company in its UK launch, according to the announcement.

Dr Weekes is the country medical director for Australia of GlaxoSmithKline (NYSE: GSK). Respiri states GlaxoSmithKline is a leading global player in respiratory diseases. Dr Weekes will provide advice to Respiri's board regarding Wheezo's commercialisation, its clinical development and other subjects.    

Dr Levy has been appointed as an advisor for the UK. He has been a member of the Global Initiative for Asthma executive board since 2009. Respiri CEO Marjan Mikel said Dr Levy has provided the board with advice and introductions ahead of its UK launch.

Respiri share price snapshot

The Respiri share price is having a stellar year on the ASX and is currently up by 23.08% year to date. It is also up by nearly 83% over the last 12 months.

The company has a market capitalisation of around $115 million, with approximately 722 million shares outstanding.

The post Why the Respiri (ASX:RSH) share price opened higher today appeared first on The Motley Fool Australia.

COVID-19 cases and deaths continue to rise in the United States. Some states are being hit especially hard. While researchers and physicians have learned a lot about the disease caused by novel coronavirus SARS-CoV-2, there seems to be no end in sight to the ongoing pandemic.

The good news, though, is that a frantic – and massive – effort is under way to develop vaccines that could potentially prevent the spread of COVID-19. Here's everything you need to know about the coronavirus vaccine race.

How many vaccine candidates are being developed?

As of July 31, 2020, there are 165 novel coronavirus vaccine candidates in development, according to the World Health Organization. However, 139 of these candidates are in preclinical testing. Many of these candidates might not advance into clinical testing in humans. The good news is that 26 COVID-19 vaccine candidates are already in clinical testing. 

Which vaccine candidates are in the lead?

Clinical testing of vaccines includes three phases. Candidates must successfully complete phase 1 testing to go on to phase 2 and then must successfully complete phase 2 testing to advance into phase 3.

There are currently five COVID-19 vaccine candidates in phase 3 testing, also commonly referred to as late-stage testing. Chinese drugmaker Sinopharm claims two of these candidates. Another Chinese company, Sinovac Biotech, also has a COVID-19 vaccine candidate in phase 3 testing. The other two late-stage candidates are AZD1222, which is being developed by AstraZeneca (NYSE: AZN) and the University of Oxford, and Moderna's (NASDAQ: MRNA) mRNA-1273.

In addition, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) recently began a phase 2/3 clinical study evaluating COVID-19 vaccine candidate BNT162b2.

How do the leading vaccine candidates differ?

The vaccine candidates from Sinopharm and Sinovac use inactivated (dead) coronavirus cells that are introduced to the body. AstraZeneca and the University of Oxford are using what's called a non-replicating viral vector. This approach uses a weakened version of an adenovirus (which causes the common cold) to deliver genetic material from the SARS-CoV-2 virus. 

Moderna and the Pfizer/BioNTech partnership use a messenger RNA (mRNA) approach. While DNA contains all of the instructions for building proteins, mRNA carries those instructions to ribosomes, which serve as the body's protein-making factories. The COVID-19 vaccine candidates developed by Moderna and Pfizer/BioNTech modify mRNA to cause ribosomes to produce spike proteins that are identical to those found in SARS-CoV-2.

The ultimate goal of all of these vaccines is to cause the body to develop antigens that remain in the blood and help fight off future viral attacks. 

Which vaccines not among the leaders could be winners?

Two COVID-19 vaccine candidates currently in clinical testing have received significant funding and appear to be especially promising. 

Novavax (NASDAQ: NVAX) received $1.6 billion from the U.S. government for developing COVID-19 vaccine candidate NVX-CoV2373. Johnson & Johnson (NYSE: JNJ) also was awarded $456 million in funding for its coronavirus vaccine candidate. 

There's also an experimental COVID-19 vaccine that hasn't advanced into clinical testing that scored a major U.S. government funding deal recently. Sanofi (NASDAQ: SNY) and GlaxoSmithKline (NYSE: GSK) were awarded $2.1 billion for up to 100 million doses of a preclinical coronavirus vaccine candidate. 

How soon might a vaccine be available?

In the past, it's taken years for vaccines to advance through clinical testing and win regulatory approvals. However, the normal timeline is being accelerated greatly as a result of the COVID-19 pandemic.

Opinions vary as to how soon a coronavirus vaccine will be available. Some CEOs of companies making vaccine candidates think their COVID-19 vaccine candidates could be ready by the end of this year. Others believe that early 2021 is more likely. However, there are also some less optimistic predictions that it could take much longer before a safe and effective COVID-19 vaccine is ready.

What are the chances that no vaccine will be safe and effective?

You'll probably be happy to learn that the chances that none of the COVID-19 vaccine candidates in development will be safe and effective are quite low. Nearly three out of four vaccines that entered phase 3 testing between 2006 and 2015 went on to win FDA approval, according to biopharmaceutical industry organization BIO. 

Since there are currently six coronavirus vaccine candidates in late-stage testing or close to it, the probability that none of them will win approval based on BIO's historical analysis is only one in 3,470. If we included all of the other candidates in phase 1 and phase 2 clinical testing, the odds are heavily in favor of at least one of them achieving success.

Which coronavirus vaccine stocks are good picks?

The Motley Fool's mission is to make the world smarter, happier, and richer. Therefore, we can't leave out addressing the investing angle of the coronavirus vaccine race. 

If your investing style is more conservative, big pharma stocks like AstraZeneca and Pfizer could be attractive. Both companies are leaders in the scramble to develop a COVID-19 vaccine. Both have landed major supply contracts already. And both AstraZeneca and Pfizer have other growth drivers in addition to their COVID-19 programs.

On the other hand, if you're an aggressive investor, Moderna and Novavax might be more to your liking. Both biotech stocks have soared this year. But if their COVID-19 vaccine candidates are successful in clinical testing, Moderna and Novavax could go a lot higher.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Everything you need to know about the coronavirus vaccine race appeared first on The Motley Fool Australia.